S&P 500   3,320.79 (-0.27%)
DOW   29,196.04 (-0.52%)
QQQ   223.28 (-0.04%)
AAPL   316.57 (-0.68%)
FB   221.44 (-0.32%)
MSFT   166.50 (-0.36%)
GOOGL   1,482.25 (+0.18%)
AMZN   1,892.00 (+1.46%)
CGC   24.15 (-2.97%)
NVDA   247.94 (-0.54%)
BABA   222.26 (-2.27%)
MU   58.97 (+2.27%)
GE   11.66 (-1.27%)
TSLA   547.20 (+7.19%)
AMD   51.05 (+0.24%)
T   38.52 (+0.36%)
ACB   2.01 (-5.63%)
F   9.21 (+0.55%)
NFLX   338.11 (-0.46%)
PRI   126.41 (-1.57%)
BAC   34.26 (-1.30%)
DIS   143.56 (-0.53%)
GILD   62.63 (-0.56%)
S&P 500   3,320.79 (-0.27%)
DOW   29,196.04 (-0.52%)
QQQ   223.28 (-0.04%)
AAPL   316.57 (-0.68%)
FB   221.44 (-0.32%)
MSFT   166.50 (-0.36%)
GOOGL   1,482.25 (+0.18%)
AMZN   1,892.00 (+1.46%)
CGC   24.15 (-2.97%)
NVDA   247.94 (-0.54%)
BABA   222.26 (-2.27%)
MU   58.97 (+2.27%)
GE   11.66 (-1.27%)
TSLA   547.20 (+7.19%)
AMD   51.05 (+0.24%)
T   38.52 (+0.36%)
ACB   2.01 (-5.63%)
F   9.21 (+0.55%)
NFLX   338.11 (-0.46%)
PRI   126.41 (-1.57%)
BAC   34.26 (-1.30%)
DIS   143.56 (-0.53%)
GILD   62.63 (-0.56%)
S&P 500   3,320.79 (-0.27%)
DOW   29,196.04 (-0.52%)
QQQ   223.28 (-0.04%)
AAPL   316.57 (-0.68%)
FB   221.44 (-0.32%)
MSFT   166.50 (-0.36%)
GOOGL   1,482.25 (+0.18%)
AMZN   1,892.00 (+1.46%)
CGC   24.15 (-2.97%)
NVDA   247.94 (-0.54%)
BABA   222.26 (-2.27%)
MU   58.97 (+2.27%)
GE   11.66 (-1.27%)
TSLA   547.20 (+7.19%)
AMD   51.05 (+0.24%)
T   38.52 (+0.36%)
ACB   2.01 (-5.63%)
F   9.21 (+0.55%)
NFLX   338.11 (-0.46%)
PRI   126.41 (-1.57%)
BAC   34.26 (-1.30%)
DIS   143.56 (-0.53%)
GILD   62.63 (-0.56%)
S&P 500   3,320.79 (-0.27%)
DOW   29,196.04 (-0.52%)
QQQ   223.28 (-0.04%)
AAPL   316.57 (-0.68%)
FB   221.44 (-0.32%)
MSFT   166.50 (-0.36%)
GOOGL   1,482.25 (+0.18%)
AMZN   1,892.00 (+1.46%)
CGC   24.15 (-2.97%)
NVDA   247.94 (-0.54%)
BABA   222.26 (-2.27%)
MU   58.97 (+2.27%)
GE   11.66 (-1.27%)
TSLA   547.20 (+7.19%)
AMD   51.05 (+0.24%)
T   38.52 (+0.36%)
ACB   2.01 (-5.63%)
F   9.21 (+0.55%)
NFLX   338.11 (-0.46%)
PRI   126.41 (-1.57%)
BAC   34.26 (-1.30%)
DIS   143.56 (-0.53%)
GILD   62.63 (-0.56%)
Log in
(Ad)
In early 2019 President Trump warned this company's biggest customers to "step up their 5G efforts." A few months later, he banned their biggest competitor from doing business in the U.S. Now, this $5 stock could turn a $10,000 stake into $234,770 this year. But timing is critical. A single mention on the evening news and this opportunity could get away from you.

NASDAQ:ATRC - AtriCure Stock Price, Forecast & News

$38.65
+0.40 (+1.05 %)
(As of 01/21/2020 04:00 PM ET)
Add
Compare
Today's Range
$37.66
Now: $38.65▼
$38.88
50-Day Range
$29.59
MA: $32.56▼
$38.65
52-Week Range
$22.57
Now: $38.65▼
$38.88
Volume373,693 shs
Average Volume372,583 shs
Market Capitalization$1.53 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.32
AtriCure, Inc develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; EPi-Sense guided coagulation system used for the coagulation of tissue; and COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy. Read More…

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:ATRC
Previous Symbol
CUSIP04963C20
CIK1323885
Webhttp://www.atricure.com/
Phone513-755-4100

Debt

Debt-to-Equity Ratio0.29
Current Ratio3.11
Quick Ratio2.49

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$201.63 million
Price / Sales7.58
Cash FlowN/A
Price / Cash FlowN/A
Book Value$6.47 per share
Price / Book5.97

Profitability

EPS (Most Recent Fiscal Year)($0.94)
Net Income$-21,140,000.00
Net Margins-10.13%
Return on Equity-13.59%
Return on Assets-8.40%

Miscellaneous

Employees620
Outstanding Shares39,550,000
Market Cap$1.53 billion
Next Earnings Date2/27/2020 (Estimated)
OptionableOptionable

Receive ATRC News and Ratings via Email

Sign-up to receive the latest news and ratings for ATRC and its competitors with MarketBeat's FREE daily newsletter.

NASDAQ:ATRC Rates by TradingView

(Ad)

In early 2019 President Trump warned this company's biggest customers to "step up their 5G efforts." A few months later, he banned their biggest competitor from doing business in the U.S. Now, this $5 stock could turn a $10,000 stake into $234,770 this year. But timing is critical. A single mention on the evening news and this opportunity could get away from you.

AtriCure (NASDAQ:ATRC) Frequently Asked Questions

What is AtriCure's stock symbol?

AtriCure trades on the NASDAQ under the ticker symbol "ATRC."

How were AtriCure's earnings last quarter?

AtriCure Inc. (NASDAQ:ATRC) released its earnings results on Wednesday, October, 30th. The medical device company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.28) by $0.03. The medical device company earned $56.60 million during the quarter, compared to the consensus estimate of $55.12 million. AtriCure had a negative net margin of 10.13% and a negative return on equity of 13.59%. The company's revenue was up 13.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.24) EPS. View AtriCure's Earnings History.

When is AtriCure's next earnings date?

AtriCure is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for AtriCure.

What guidance has AtriCure issued on next quarter's earnings?

AtriCure issued an update on its fourth quarter 2019 Pre-Market earnings guidance on Monday, January, 13th. The company provided EPS guidance of for the period. The company issued revenue guidance of $61.3-61.3 million, compared to the consensus revenue estimate of $59.24 million.

What price target have analysts set for ATRC?

5 equities research analysts have issued 1 year price objectives for AtriCure's shares. Their forecasts range from $30.00 to $42.00. On average, they expect AtriCure's share price to reach $37.60 in the next year. This suggests that the stock has a possible downside of 2.7%. View Analyst Price Targets for AtriCure.

What is the consensus analysts' recommendation for AtriCure?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AtriCure in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AtriCure.

Has AtriCure been receiving favorable news coverage?

Media stories about ATRC stock have been trending somewhat positive on Tuesday, InfoTrie Sentiment reports. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. AtriCure earned a news sentiment score of 2.0 on InfoTrie's scale. They also assigned media headlines about the medical device company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for AtriCure.

Who are some of AtriCure's key competitors?

What other stocks do shareholders of AtriCure own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AtriCure investors own include AbbVie (ABBV), Amgen (AMGN), Gilead Sciences (GILD), Neurocrine Biosciences (NBIX), Enterprise Products Partners (EPD), Cellectis (CLLS), Abbott Laboratories (ABT), Alnylam Pharmaceuticals (ALNY), bluebird bio (BLUE) and DexCom (DXCM).

Who are AtriCure's key executives?

AtriCure's management team includes the folowing people:
  • Mr. Michael H. Carrel, CEO, Pres & Director (Age 48)
  • Mr. M. Andrew Wade CPA, Sr. VP & CFO (Age 44)
  • Mr. Douglas J. Seith, Chief Operating Officer (Age 53)
  • Mr. Salvatore Privitera, Chief Technology Officer (Age 52)
  • Mr. Justin J. Noznesky, Sr. VP of Marketing & Bus. Devel. (Age 41)

Who are AtriCure's major shareholders?

AtriCure's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Peregrine Capital Management LLC (1.93%). Company insiders that own AtriCure stock include Douglas J Seith, Elizabeth D Krell, Justin J Noznesky, M Andrew Wade, Mark A Collar, Michael H Carrel and Regina E Groves. View Institutional Ownership Trends for AtriCure.

Which institutional investors are selling AtriCure stock?

ATRC stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC. Company insiders that have sold AtriCure company stock in the last year include Douglas J Seith, Justin J Noznesky, M Andrew Wade, Mark A Collar and Michael H Carrel. View Insider Buying and Selling for AtriCure.

How do I buy shares of AtriCure?

Shares of ATRC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is AtriCure's stock price today?

One share of ATRC stock can currently be purchased for approximately $38.65.

How big of a company is AtriCure?

AtriCure has a market capitalization of $1.53 billion and generates $201.63 million in revenue each year. The medical device company earns $-21,140,000.00 in net income (profit) each year or ($0.94) on an earnings per share basis. AtriCure employs 620 workers across the globe.View Additional Information About AtriCure.

What is AtriCure's official website?

The official website for AtriCure is http://www.atricure.com/.

How can I contact AtriCure?

AtriCure's mailing address is 7555 INNOVATION WAY, MASON OH, 45040. The medical device company can be reached via phone at 513-755-4100.


MarketBeat Community Rating for AtriCure (NASDAQ ATRC)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  439 (Vote Outperform)
Underperform Votes:  323 (Vote Underperform)
Total Votes:  762
MarketBeat's community ratings are surveys of what our community members think about AtriCure and other stocks. Vote "Outperform" if you believe ATRC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATRC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/21/2020 by MarketBeat.com Staff

Featured Article: Why are percentage gainers important?
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel